What is current guideline-recommended medical therapy for #HFrEF? #ESCCongress @escardio

NIH funding rates for early-career researchers plunged in 2025, new data show https://t.co/RWqf8lfBE9 via @statnews @AJIAorg

Wish you all have wonderful holidays season! #HappyHolidays #FestiveSeason

#OPTIPHARM-HF (N=3054, 32 Italian centers): Mean age: 69 ± 12 years | 25% female 📍56% HFrEF / 21% HFmrEF / 23% HFpEF. HFrEF on #GDMT: BB 90%, ACEi/ARB 19%, ARNI 61%, MRA 72%, SGLT2i 69%. 📍Quadruple therapy ↑ from 47% → 64% after 1st visit (p<0.001). 📍#SGLT2i use ↑ to

📌 Which medications should we avoid in HF patients ⁉️ This position 🗞️ provides a very practical guide in daily clinical practice. 📄 A must-read for clinicians caring for HF pts. 🔗 https://t.co/0YdRsmR0Xh @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd #EJHF

Long-Term Effect of #ICDs in Nonischemic #HFrEF #DANISH Study – Extended Follow-up (median 13.2 yrs) N=1,116 nonischemic #HFrEF (LVEF ≤35%, NYHA II–III) 📍ICD vs usual care 📍All-cause ☠️: no benefit (HR 0.96; 95% CI 0.82–1.13) 📍Sudden CV ☠️: reduced (HR 0.54; 95% CI

Insurance Coverage and Pricing of Weight-Loss Drugs in the United States https://t.co/zjbdzWXtmO @NEJM

🗞️ Combination diuretic therapy in acute heart failure: A systematic review and meta-analysis @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd https://t.co/UHj1x7lIV1

Not All Hospitalized Heart Failure Patients Are the Same: A New Worldview https://t.co/VOxNEF9BbI @JACCJournals

PRECISION (CKD + resistant HTN): 📍Office SBP ↓ 16.6 mmHg, Nighttime SBP ↓ 13.8 mmHg at week 4 📍Albuminuria ↓ 59.6%, maintained to week 36; well tolerated, early edema most common #PRECISIONstudy #CKD #Hypertension https://t.co/14Epqgbd9S @HyperAHA

🚫Harmful Drugs in Heart Failure!💊 A position 🗞️to guide drugs that may cause or exacerbate HF 👉 https://t.co/P41ljOTJdg @JBauersachsMD @SulemanAktaa @JavedButler1 @mvaduganathan @GianluSava @HFA_President @JanBiegus @MagdyAbdelhami7 @NicolasGirerd @WilfriedMullens

4/ What unites us is not only our passion for imaging, but our shared commitment to clinical excellence and the care of patients we deeply care for. This spirit was felt throughout the congress.

1️⃣ How to use GLP-1 RA in patients with #HeartFailure? New #EJHF expert consensus document, a thread🧵: 📍Eligible pts: #HFpEF + #obesity (BMI ≥30 kg/m2) 📍Avoid/caution: #HFrEF, #worseningHF, #ESRD, prior pancreatitis, severe GI intolerance 📍Start low, titrate every 4 weeks

2️⃣ GLP-1 RAs may play different roles across the #HeartFailure continuum: 📍Stage A (at-risk): #cardiometabolic benefits may prevent transition to #HF 📍Stage B (pre-HF): weight loss & metabolic improvement may slow HF progression 📍Stage C: reduce weight, improve symptoms in

3️⃣ Managing #GI intolerance is essential for safe GLP-1 RA use in #HF Practical strategies include: 📍Start low, titrate slowly💉 📍Eat slowly, smaller portions, avoid eating close to bedtime, avoid drinking with straw🥤 📍Choose low-fat, easy-to-digest foods 📍Nausea: eat

📌Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies 2025 @ACCinTouch Concise Clinical #Guidance #CardiOnc #CardioOncology #Review #Guidelines

Insurance Coverage and Pricing of Weight-Loss Drugs in the United States https://t.co/zjbdzWXtmO @NEJM

Retatrutide just set a new bar. 🧬 In TRIUMPH-4, Lilly’s triple agonist delivered ~28.7% body-weight loss (~71 lbs at 68 weeks) and major knee OA pain relief (WOMAC ↓ 4.5 points, 75.8%). Obesity, pain, and function being hit with one shot. The metabolic era is just getting

2015: barely a blip. 2025: tens of millions of Rx. 📈 GLP-1/GIP agonists (Ozempic, Wegovy, Mounjaro, Zepbound) aren’t just a fad—they’re a true therapeutic revolution, finally letting us treat obesity-related metabolic disease at its biologic root instead of just patching the

🔥Debate at #EACVI2025: Should #LGE always be quantified in Non-Ischemic #LV scar? Not so fast🚫, argument by @JccmoonMoon 📍Biology is complex, quantification oversimplifies it - #Fibrosis, #edema, #amyloid, focal vs diffuse patterns → all behave differently - #LGE is a

🔥Debate at #EACVI2025: Should #LGE always be quantified in Non-ischemic #LV scar? Pro: Why it should always be quantified by @carlosrochitte 📍Risk rises progressively: #DCM → ↑events per 1% LV LGE #HCM → high risk (≥15%) #Ischemic → scar + gray zone predict VT/VF 📍Risk